Stock Scorer

Assembly Biosciences, Inc. (ASMB)

Assembly Biosciences, Inc. reported revenue of 13.4M USD for the quarter ending 30 June 2026, up 42.0% from 9.4M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 13.4M +42.0%
Operating Income Q2 '26 · ending 30 June 2026 -6.3M —
Net Income Q2 '26 · ending 30 June 2026 -3.9M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -15.5M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -15.5M —
Shares Outstanding Q2 '26 · ending 30 June 2026 18.9M +151.2%
EPS Q2 '26 · ending 30 June 2026 1.21 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 72.3M-12.1M-6.1M-41.2M
20242024-12-31 28.5M-45.4M-40.2M-51.1M
20232023-12-31 7.2M-64.6M-61.2M22.5M
20222022-12-31 0-94.1M-93.1M-84.6M
20212021-12-31 6.3M-132.7M-129.9M-96.5M
20202020-12-31 79.1M-64.8M-62.2M-63.4M
20192019-12-31 16M-102.7M-97.6M-85.6M
20182018-12-31 14.8M-92.7M-90.8M-65.3M
20172017-12-31 9M-52.2M-42.8M995K
20162016-12-31 0-45.3M-44.3M-35M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3013.4M
Q1 '262026-03-318.2M
Q3 '252025-09-3010.8M
Q2 '252025-06-309.6M
Q1 '252025-03-319.4M
Q4 '242024-12-317.4M
Q3 '242024-09-306.8M
Q2 '242024-06-308.5M
Q1 '242024-03-315.8M
Q4 '232023-12-317.2M
Q3 '232023-09-300
Q2 '232023-06-300
Q1 '232023-03-310
Q4 '212021-12-310
Q3 '212021-09-306.3M
Q4 '202020-12-311M
Q3 '202020-09-3034.6M
Q2 '202020-06-3039.4M
Q1 '202020-03-314.1M
Q4 '192019-12-314.8M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-6.3M
Q1 '262026-03-31-11.4M
Q4 '252025-12-3119.8M
Q3 '252025-09-30-10.9M
Q2 '252025-06-30-11.1M
Q1 '252025-03-31-9.9M
Q4 '242024-12-31-11.5M
Q3 '242024-09-30-11M
Q2 '242024-06-30-12.2M
Q1 '242024-03-31-10.7M
Q4 '232023-12-31-12.6M
Q3 '232023-09-30-15M
Q2 '232023-06-30-17.5M
Q1 '232023-03-31-19.6M
Q4 '222022-12-31-23M
Q3 '222022-09-30-23.4M
Q2 '222022-06-30-24.6M
Q1 '222022-03-31-23.2M
Q4 '212021-12-31-62.9M
Q3 '212021-09-30-18.9M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-3.9M
Q1 '262026-03-31-9.1M
Q4 '252025-12-3122.1M
Q3 '252025-09-30-9.2M
Q2 '252025-06-30-10.2M
Q1 '252025-03-31-8.8M
Q4 '242024-12-31-10.3M
Q3 '242024-09-30-9.6M
Q2 '242024-06-30-11.2M
Q1 '242024-03-31-9.1M
Q4 '232023-12-31-11M
Q3 '232023-09-30-14.4M
Q2 '232023-06-30-16.9M
Q1 '232023-03-31-18.9M
Q4 '222022-12-31-22.4M
Q3 '222022-09-30-23.1M
Q2 '222022-06-30-24.5M
Q1 '222022-03-31-23.1M
Q4 '212021-12-31-60.3M
Q3 '212021-09-30-18.8M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-15.5M
Q1 '262026-03-31-22.1M
Q4 '252025-12-3114.2M
Q3 '252025-09-30-15.1M
Q2 '252025-06-30-16.8M
Q1 '252025-03-31-23.4M
Q4 '242024-12-31-407K
Q3 '242024-09-30-15.2M
Q2 '242024-06-30-17.1M
Q1 '242024-03-31-18.4M
Q3 '232023-09-30-13.8M
Q2 '232023-06-30-13.6M
Q1 '232023-03-31-23.4M
Q4 '222022-12-31-19.3M
Q3 '222022-09-30-19.8M
Q2 '222022-06-30-17.9M
Q1 '222022-03-31-27.5M
Q4 '212021-12-31-19.4M
Q3 '212021-09-30-18.9M
Q2 '212021-06-30-21.8M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-15.5M
Q1 '262026-03-31-22.1M
Q4 '252025-12-3114.2M
Q3 '252025-09-30-15.2M
Q2 '252025-06-30-16.8M
Q1 '252025-03-31-23.4M
Q4 '242024-12-31-407K
Q3 '242024-09-30-15.2M
Q2 '242024-06-30-17.1M
Q1 '242024-03-31-18.4M
Q3 '232023-09-30-14M
Q2 '232023-06-30-13.7M
Q1 '232023-03-31-23.4M
Q4 '222022-12-31-19.3M
Q3 '222022-09-30-19.9M
Q2 '222022-06-30-17.9M
Q1 '222022-03-31-27.5M
Q4 '212021-12-31-19.4M
Q3 '212021-09-30-18.9M
Q2 '212021-06-30-21.8M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3018.9M
Q1 '262026-03-3116.9M
Q3 '252025-09-3012.7M
Q2 '252025-06-307.7M
Q1 '252025-03-317.5M
Q3 '242024-09-306.4M
Q2 '242024-06-305.6M
Q1 '242024-03-315.5M
Q3 '232023-09-304.4M
Q2 '232023-06-304.4M
Q1 '232023-03-314.3M
Q3 '222022-09-3048.4M
Q2 '222022-06-3048.3M
Q1 '222022-03-3148.1M
Q3 '212021-09-3045.6M
Q2 '212021-06-3042.9M
Q2 '202020-06-3037.3M
Q1 '202020-03-3135.1B
Q3 '192019-09-3025.9M
Q2 '192019-06-3025.7M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-301.21
Q1 '262026-03-310.08
Q4 '252025-12-31-0.55
Q3 '252025-09-30-4.79
Q2 '252025-06-30-5.58
Q1 '252025-03-31-6.23
Q4 '242024-12-31-6.72
Q3 '242024-09-30-6.92
Q2 '242024-06-30-8.70
Q1 '242024-03-31-10.60
Q4 '232023-12-31-13.40
Q3 '232023-09-30-33.25
Q2 '232023-06-30-30.44
Q1 '232023-03-31-27.07
Q4 '222022-12-31-23.09
Q3 '222022-09-30-2.84
Q2 '222022-06-30-2.77
Q1 '222022-03-31-2.81
Q4 '212021-12-31-3.02
Q3 '212021-09-30-2.76